Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing cancer therapy candidates in the United States. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody currently in Phase 3 clinical trials for treating solid tumors. The company also has earlier-stage candidates CR-002 and CR-003. Crescent Biopharma has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. and was founded in 2024, headquartered in Waltham, Massachusetts.

Crescent Biopharma, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CBIO. Its shares are traded in United States Dollars (USD). The company is headquartered in Waltham, Massachusetts, and operates primarily in the United States.

Crescent Biopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative cancer therapies, including bispecific antibodies for solid tumors. The company's work involves clinical-stage drug development, with its lead candidate CR-001 in Phase 3 trials.

Crescent Biopharma is headquartered in Waltham, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its operations being based in the country. Its strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. suggests a collaborative approach to developing oncology therapeutics, potentially extending its reach to global markets, though its core focus remains on the United States.

Crescent Biopharma's business model centers on researching and developing cancer therapy candidates, with the goal of advancing them through clinical trials and ultimately commercializing them. The company's pipeline includes CR-001, a bispecific antibody in Phase 3 trials for solid tumors, as well as earlier-stage candidates CR-002 and CR-003. Revenue generation typically involves licensing deals, partnerships, and potential future product sales. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, which may include milestone payments and royalties. As a clinical-stage biotechnology firm, it likely does not yet have approved products generating significant revenue.